Eleven Biotherapeutics, Inc. (EBIO) Sees Strong Trading Volume

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) saw strong trading volume on Tuesday . 1,968,959 shares were traded during mid-day trading, an increase of 695% from the previous session’s volume of 247,645 shares.The stock last traded at $1.61 and had previously closed at $1.45.

Separately, ValuEngine lowered shares of Eleven Biotherapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, June 13th.

The stock has a 50-day moving average of $1.27 and a 200 day moving average of $1.60. The company has a market capitalization of $24.78 million, a P/E ratio of 14.77 and a beta of 3.37.

Eleven Biotherapeutics (NASDAQ:EBIO) last announced its quarterly earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter. Eleven Biotherapeutics had a net margin of 11.28% and a return on equity of 4.26%. Equities research analysts predict that Eleven Biotherapeutics, Inc. will post ($1.75) EPS for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Spark Investment Management LLC bought a new stake in Eleven Biotherapeutics in the 2nd quarter valued at $148,000. Virtu KCG Holdings LLC bought a new stake in Eleven Biotherapeutics in the 2nd quarter valued at $175,000. Finally, Vanguard Group Inc. increased its holdings in Eleven Biotherapeutics by 17.4% in the 2nd quarter. Vanguard Group Inc. now owns 206,450 shares of the biopharmaceutical company’s stock valued at $324,000 after acquiring an additional 30,600 shares during the last quarter. Institutional investors own 5.05% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Eleven Biotherapeutics, Inc. (EBIO) Sees Strong Trading Volume” was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2017/09/19/eleven-biotherapeutics-inc-ebio-sees-strong-trading-volume.html.

Eleven Biotherapeutics Company Profile

Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.

Receive News & Ratings for Eleven Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply